Additional Research Studies Being Conducted by the ITN
Type 1 Diabetes Clinical Trials
T1DES is a clinical study for people with type 1 diabetes who were previously enrolled in an ITN clinical study.
Autoimmune Disease Clinical Trials
Efficacy of Ustekinumab followed by Abatacept for the Treatment of Psoriasis Vulgaris (PAUSE)
PAUSE is a clinical trial testing the effectiveness of ustekinumab (STELARA ®) followed by an investigational drug, abatacept, for the treatment of psoriasis. The main goal of the study is to determine the efficacy of abatacept to induce prolonged remission.
Rituximab Plus Cyclophosphamide followed by Belimumab (CALIBRATE)
CALIBRATE is a clinical research study testing the safety and efficacy of an investigational drug approach in lupus nephritis: treatment with rituximab (Rituxan®) and cyclophosphamide (Cytoxan®) followed by belimumab (Benlysta®).
Allergy Clinical Trials
IMPACT is a clinical research study testing whether daily oral exposure to a peanut product can modify peanut allergy in young children.
GRASS – Long-Term Effects of Sublingual Grass Therapy
This study is testing the effectiveness of two commercially available tolerance-increasing treatments for hay fever to induce long-term tolerance.
CAT EEC – Cat Pilot Study - Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC)
The goal of this study is to compare allergic responses to cat by environmental exposure chamber vs. nasal allergen challenge to better understand and employ these methods as allergy evaluation tools in clinical trials.
Transplantation Clinical Trials
A clinical trial investigating immunosuppression withdrawal in liver transplant recipients.
A study to assess the ability of a specialized pre-transplant conditioning regimen, bone marrow transplantation and high dose post-transplant cyclophosphamide, to induce tolerance and enable long-term discontinuation of immunosuppression in kidney transplant recipients.
RESTARRT – Research Study of ATG and Rituximab in Renal Transplantation.
A clinical trial testing whether a combination of anti-thymocyte globulin (ATG), rituximab, mycophenolate mofetil, tacrolimus and sirolimus can reset the immune system of kidney transplant recipients to help it accept the transplanted kidney without the need for life-long immunosuppression.
For more information about the ITN and other clinical trials, please visit immunetolerance.org.